^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    18h
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Shenzhen Ionova Life Sciences Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    18h
    3082-CL-0301: A study to confirm the safety of ASP3082, and if it delays tumor growth in people with pancreatic cancer, when given with either mFOLFIRINOX or NALIRIFOX chemotherapies (2025-523684-38-00)
    P2/3, N=35, Not yet recruiting, Astellas Pharma Global Development Inc.
    New P2/3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • setidegrasib (ASP3082) • Onivyde (nanoliposomal irinotecan)
    18h
    VS-7375-101: A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors (2025-523432-39-01)
    P1/2, N=120, Not yet recruiting, Verastem Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    18h
    GS-US-741-7756: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer. (2025-523984-39-00)
    P1/2, N=75, Not yet recruiting, Gilead Sciences Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • RAS wild-type • KRAS G12
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • denikitug (GS-1811)
    21h
    Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    22h
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Recruiting, Amgen | Trial completion date: Aug 2031 --> Apr 2032 | Trial primary completion date: Jan 2028 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    2d
    A Rare Presentation of Multiple Primary Cancers with Extensive Abdominopelvic Cross-Metastasis and Tumor-to-Tumor Metastasis: High-Grade Serous Carcinoma of the Ovary and Well-Differentiated Mucinous Adenocarcinoma of the Appendix. (PubMed, Int J Surg Pathol)
    Our findings emphasize that when imaging or cytology suggests multiorigin components, clinicians should pursue thorough intraoperative exploration, multisite biopsies, and prophylactic appendectomy. Ultimately, the management of such patients requires highly individualized surgical and chemotherapeutic strategies that account for the divergent biological behaviors and therapeutic sensitivities of both HGSOC and well-differentiated appendiceal mucinous adenocarcinoma to optimize oncological outcomes.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • WT1 (WT1 Transcription Factor) • GNAS (GNAS Complex Locus) • KRT20 (Keratin 20) • PAX8 (Paired box 8)
    |
    TP53 mutation • KRAS mutation • KRAS G12D • KRAS G12
    3d
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12D • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • RET rearrangement • KRAS G12 • KRAS G12S • KRAS Q61
    |
    D3S-002 • elisrasib (D3S-001)
    3d
    Optimized Preparation of Whole Murine Tumor-Bearing Lung Tissue for Flow Cytometry and Single-Cell RNA-Sequencing. (PubMed, J Vis Exp)
    The procedure includes tissue perfusion, controlled enzymatic digestion, gentle mechanical dissociation, red blood cell lysis, filtration, and viability assessment, and achieves >85% viable cells prior to scRNA-seq. Finally, the tdTomato+ tumor cells are efficiently isolated by FACS and can be detected as distinct clusters by scRNA-seq using this protocol.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12D • KRAS G12
    3d
    Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs. (PubMed, Int J Cancer)
    Overall survival analysis showed no consistent prognostic disadvantage for CO, except in EGFR-KRAS co-mutant NSCLC. These findings further refine the ME landscape of BRAF, KRAS, and EGFR variants, offering a variant-level reference to support mutation-informed precision oncology.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • EGFR exon 19 deletion • KRAS G12D • KRAS G12
    3d
    YKYY031，tumors: Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=76, Not yet recruiting, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    BRAF V600E • KRAS G12C • BRAF V600 • KRAS G12D • KRAS G13D • KRAS G12R • KRAS G12 • KRAS G12S • KRAS G13
    3d
    A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation (clinicaltrials.gov)
    P3, N=356, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    docetaxel • setidegrasib (ASP3082)